ArticleIDCases2026
Disseminated mpox with suspected immune reconstitution inflammatory syndrome in a person living with HIV: A case report from South Kivu, Democratic Republic of the Congo.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe mpox is increasingly reported in people living with HIV (PLHIV). While immune reconstitution inflammatory syndrome (IRIS) is well-characterised in other opportunistic infections, its role in the acute clinical course of mpox remains poorly understood. Case presentation: A 42-year-old man from eastern South Kivu, Democratic Republic of the Congo (DRC), with newly diagnosed HIV initiated tenofovir/lamivudine/dolutegravir. Two weeks later, he developed severe disseminated clade I mpox, confirmed by PCR, with more than 250 polymorphic lesions. Around day 7 of admission, while afebrile, he experienced paradoxical clinical worsening with confluent hemorrhagic and necrotic plaques, which were highly suggestive of mpox-associated IRIS. A pragmatic management protocol consisting of a 6-week tapered course of oral prednisone, broad-spectrum oral antibiotics (levofloxacin and clindamycin), high-dose acyclovir, and supportive care led to progressive skin healing and clinical recovery while ART was continued. He was discharged after 62 days at the family's request. Unfortunately, 3.5 weeks post-discharge, he died at home following the application of traditional topical preparations to residual lesions. Conclusions: This case highlights the need to consider mpox-associated IRIS in the differential diagnosis of unexplained clinical worsening of mpox in PLHIV who recently initiated ART. Although definitive confirmation of IRIS was not possible because of limited immunological investigations, the temporal association with ART initiation and the clinical course were consistent with this diagnosis. This case underscores the need for standardized diagnostic criteria, prospective evaluation of adjunctive anti-inflammatory therapies, and strengthened post-discharge community follow-up in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.